Concepedia

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

David S. Hong, Razelle Kurzrock, Aung Naing, Jennifer J. Wheler, Gerald S. Falchook, Jade S. Schiffman, Neil Faulkner, Mary Jo Pilat, James P. O’Brien, Patricia LoRusso

Investigational New Drugs · 2013 · 211 citations · 15 references

DOI

Concepts

References

15

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts

Elli Papaemmanuil, Mario Cazzola, Jacqueline Boultwood et al. · New England Journal of Medicine · 2011 · 1.2K citations · Full text

, , +13

Splicing factor SF3b as a target of the antitumor natural product pladienolide

Yoshihiko Kotake, Koji Sagane, Takashi Owa et al. · Nature Chemical Biology · 2007 · 659 citations · Full text

, , +9

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Richard Simon, Larry Rubinstein, Susan G. Arbuck et al. · JNCI Journal of the National Cancer Institute · 1997 · 640 citations · Full text

, , +17

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

Davide Rossi, Alessio Bruscaggin, Valeria Spina et al. · Blood · 2011 · 369 citations · Full text

, , +10